# Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions

> **NCT04070794** · PHASE1 · UNKNOWN · sponsor: **LG Chem** · enrollment: 24 (estimated)

## Conditions studied

- Type2 Diabetes

## Interventions

- **DRUG:** Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fasting)
- **DRUG:** Gemigliptin/Metformin Hydrochloride Sustained Release 50/1000 mg(Fed)

## Key facts

- **NCT ID:** NCT04070794
- **Lead sponsor:** LG Chem
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11-01
- **Primary completion:** 2019-11-30
- **Final completion:** 2019-12-30
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04070794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04070794, "Food-effect Bioavailability of Fixed Dose Combination Zemimet® SR Tab. 50/1000 mg Under Fed and Fasting Conditions". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04070794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*